Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MnB rLP2086 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MnB rLP2086 | BIOLOGICAL | - |
Inclusion Criteria: * Healthy 18-25 year olds Exclusion Criteria: * Prior history of vaccination with any meningococcal vaccine * Prior history of any invasive meningococcal disease
MnB rLP2086 is an investigational vaccine being studied for the prevention of meningitis and meningococcal disease. It is a meningococcal group B vaccine candidate developed by Pfizer, Inc. (PFE). The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MnB rLP2086 is being developed by Pfizer, Inc. (PFE), a multinational pharmaceutical company. The drug is an investigational meningococcal group B vaccine candidate intended for the prevention of meningitis and meningococcal disease. It is currently in Phase 1 clinical development.
MnB rLP2086 is in Phase 1 clinical development. It is an investigational vaccine candidate for meningitis and meningococcal disease, developed by Pfizer, Inc. (PFE). The drug has not been approved and remains in early-stage clinical testing.
MnB rLP2086 has been studied in one completed Phase 1 clinical trial, NCT00297687, titled 'Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults.' The trial enrolled 108 healthy adult participants in Australia and was completed.
MnB rLP2086 is classified as a monoclonal antibody modality, but it is being developed as a meningococcal group B vaccine candidate. It is intended to prevent meningitis and meningococcal disease. The drug is in Phase 1 clinical development by Pfizer, Inc. (PFE).